Oak Thistle LLC Grows Stock Holdings in Enovis Corporation (NYSE:ENOV)

Oak Thistle LLC raised its holdings in shares of Enovis Corporation (NYSE:ENOV - Free Report) by 192.8% in the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 21,625 shares of the company's stock after purchasing an additional 14,240 shares during the period. Oak Thistle LLC's holdings in Enovis were worth $826,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in the business. Quadrant Capital Group LLC grew its holdings in shares of Enovis by 53.0% during the fourth quarter. Quadrant Capital Group LLC now owns 690 shares of the company's stock valued at $30,000 after buying an additional 239 shares during the last quarter. California State Teachers Retirement System boosted its holdings in Enovis by 0.7% in the fourth quarter. California State Teachers Retirement System now owns 52,236 shares of the company's stock worth $2,292,000 after purchasing an additional 350 shares during the last quarter. Xponance Inc. boosted its holdings in Enovis by 7.8% in the fourth quarter. Xponance Inc. now owns 6,380 shares of the company's stock worth $280,000 after purchasing an additional 462 shares during the last quarter. Farther Finance Advisors LLC boosted its holdings in Enovis by 266.7% in the first quarter. Farther Finance Advisors LLC now owns 737 shares of the company's stock worth $27,000 after purchasing an additional 536 shares during the last quarter. Finally, Treasurer of the State of North Carolina boosted its holdings in Enovis by 2.5% in the fourth quarter. Treasurer of the State of North Carolina now owns 24,347 shares of the company's stock worth $1,068,000 after purchasing an additional 590 shares during the last quarter. Institutional investors own 98.45% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on ENOV. Needham & Company LLC dropped their price target on shares of Enovis from $64.00 to $57.00 and set a "buy" rating on the stock in a research note on Friday, May 9th. JMP Securities dropped their price target on shares of Enovis from $62.00 to $55.00 and set a "market outperform" rating on the stock in a research note on Friday, May 9th. Canaccord Genuity Group dropped their price target on shares of Enovis from $75.00 to $70.00 and set a "buy" rating on the stock in a research note on Wednesday, May 14th. Finally, Evercore ISI dropped their price target on shares of Enovis from $48.00 to $46.00 and set an "outperform" rating on the stock in a research note on Tuesday, July 8th. One research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $55.60.

Enovis Price Performance

NYSE ENOV traded up $0.37 on Friday, reaching $27.53. The company had a trading volume of 1,126,050 shares, compared to its average volume of 1,855,950. The firm's 50 day moving average price is $31.86 and its 200 day moving average price is $36.73. Enovis Corporation has a 12 month low of $25.93 and a 12 month high of $49.83. The company has a quick ratio of 1.32, a current ratio of 2.55 and a debt-to-equity ratio of 0.52. The stock has a market capitalization of $1.57 billion, a PE ratio of -1.97 and a beta of 1.70.

Enovis (NYSE:ENOV - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported $0.81 earnings per share for the quarter, topping analysts' consensus estimates of $0.74 by $0.07. Enovis had a negative net margin of 37.65% and a positive return on equity of 5.99%. The firm had revenue of $558.83 million for the quarter, compared to the consensus estimate of $558.80 million. During the same period in the previous year, the firm posted $0.50 EPS. The business's quarterly revenue was up 8.2% on a year-over-year basis. As a group, equities analysts predict that Enovis Corporation will post 2.79 earnings per share for the current year.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.